Cancer Anorexia-Cachexia Syndrome Drugs Pipeline Landscape Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cancer Anorexia-Cachexia Syndrome (Oncology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2021, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.

Cancer anorexia-cachexia syndrome is defined as progressive weight loss associated with malignancy and is characterized by loss of appetite (anorexia), skeletal muscle wasting, and reduced adipose tissue. Approximately 50% of cancer patients report abnormalities of eating behavior at the time of first diagnosis and prevalence is even higher at approximately 65%. The incidence of weight loss upon diagnosis varies greatly according to the tumor site.

Report Highlights

The publisher’s Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 5, 2, 1, 12 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).
• The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)

Key Topics Covered:

• Introduction
• Cancer Anorexia-Cachexia Syndrome – Overview
• Cancer Anorexia-Cachexia Syndrome – Therapeutics Development
• Cancer Anorexia-Cachexia Syndrome – Therapeutics Assessment
• Cancer Anorexia-Cachexia Syndrome – Companies Involved in Therapeutics Development
• Cancer Anorexia-Cachexia Syndrome – Drug Profiles
• Cancer Anorexia-Cachexia Syndrome – Dormant Projects
• Cancer Anorexia-Cachexia Syndrome – Discontinued Products
• Cancer Anorexia-Cachexia Syndrome – Product Development Milestones
• Appendix

Companies Mentioned

• AAVogen Inc
• Abreos Biosciences Inc
• Actimed Therapeutics Ltd
• Aeterna Zentaris Inc
• Aphios Corp
• Artelo Biosciences Inc
• AVEO Pharmaceuticals Inc
• Betula Pharma
• Cannabics Pharmaceuticals Inc
• Creative Medical Technology Holdings Inc
• Energenesis Biomedical Co Ltd
• Extend Biosciences Inc
• FibroGenesis LLC
• Helsinn Group
• Immuneering Corp
• MGC Pharmaceuticals Ltd
• NGM Biopharmaceuticals Inc
• Oneness Biotech Co Ltd
• Paradigm Biopharmaceuticals Ltd
• Pfizer Inc
• RaQualia Pharma Inc
• Signablok Inc
• TCI Peptide Therapeutics
• Vascular BioSciences
• Zeria Pharmaceutical Co Ltd

For more information about this report visit https://www.researchandmarkets.com/r/1hpoz0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900